Mazyar Shadman, MD, MPH
15 Years of Experience
Physician
Seattle Cancer Care Alliance
Seattle Cancer Care Alliance
Assistant Professor, Oncology
University of Washington School of Medicine
University of Washington School of Medicine
Assistant Member, Clinical Research Division
Fred Hutchinson Cancer Research Center
Fred Hutchinson Cancer Research Center
Clinical expertise
Blood disorders
Blood disorders
Located at
“Your positive attitude and willingness to fight have always inspired me.”
—
Dr. Shadman
What do you enjoy about being an academic physician?
Every day, I get to integrate science with the art of human interaction. Seeing patients benefit from medical advances, and being active in pushing the science forward, is extremely rewarding. It’s an exciting time for both cancer care and research. We now have access to a variety of novel therapies that enable us to target cancer cells more specifically without causing major side effects. In my field, we’re always looking for a “cure,” but in the meantime, I’m hopeful that we can relegate cancer to a chronic disease and help patients maintain their desired quality of life.
Specialties and clinical expertise
The branch of medicine a provider practices and their areas of focus
Hematology-Oncology
Hematology-Oncology
Lymphomas
I am a medical oncologist and stem-cell transplant expert who specializes in treating patients with lymphomas and other blood disorders. My clinical trial work focuses on testing novel agents for the treatment of leukemia and lymphoma, with a particular focus on chronic lymphocytic leukemia (CLL). I also study the clinical outcomes of patients who have already been treated. My goal is to identify patient- or disease-specific characteristics that can help us understand the behavior of a disease and predict its responsiveness to different treatments. One particular area of interest is the epidemiology of hematologic neoplasms (abnormal growth in blood-forming tissue). In 2013, I co-authored a study that found a correlation between certain types of allergies and blood cancers.
What is your role in cancer treatment?
A diagnosis of cancer kicks off a torrent of life changes, and in the middle of all this disruption are many important decisions to make about your care. My role is to help you thoroughly understand and weigh your options. At SCCA, you have access to a variety of standard and experimental treatments, from chemotherapy to more novel, targeted approaches that may have fewer side effects. We’ll discuss each option in detail — the potential benefits, the risks and the overall impact on your life and family — so that you can make the best choices for your unique situation.
Medical Degree
Tehran University of Medical Sciences
Tehran University of Medical Sciences
Residency
Cleveland Clinic Foundation, Internal Medicine
Cleveland Clinic Foundation, Internal Medicine
Fellowship
University of Washington, Hematology-Oncology
University of Washington, Hematology-Oncology
Board Certification
Medical Oncology, 2014; Hematology, 2014; Internal Medicine, 2011, American Board of Internal Medicine
Medical Oncology, 2014; Hematology, 2014; Internal Medicine, 2011, American Board of Internal Medicine
Other
MPH, University of Washington
MPH, University of Washington
Languages
English, Persian
Your care team
At SCCA, you receive care from a team of providers with extensive experience in your disease. Your team includes doctors, a team coordinator, a registered nurse, an advanced practice provider and others, based on your needs. You also have access to experts like nutritionists, social workers, acupuncturists, psychiatrists and more who specialize in supporting people with cancer or blood disorders.
Registered nurse (RN)
Your nurse manages your care alongside your physician and assists with care procedures and
treatments.
Team coordinator (TC)
Your team coordinator works closely with you and your physician and serves as your scheduler.
Clinical trials
We make promising new treatments available to you through studies called clinical trials led by SCCA doctors. Many of these trials at SCCA have led to FDA-approved treatments and have improved standards of care globally. Together, you and your doctor can decide if a study is right for you.
An Open-Label Study to Evaluate the Safety and Efficacy of Ublituximab in Combination With TGR-1202 for Patients Previously Enrolled in Protocol UTX-TGR-304
Study No:
NCT02656303
Phase:
Phase III
Study of Pembrolizumab in Combination With Ublituximab and TGR-1202 in Patients With Relapsed-refractory CLL or Richter's Transformation
Study No:
NCT02535286
Phase:
Phase I/II
A Safety and Pharmacokinetic Study of BTCT4465A (Mosunetuzumab) as a Single Agent and Combined With Atezolizumab in Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)
Study No:
NCT02500407
Phase:
Phase I
Immunotherapy After Chemotherapy in Treating Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma
Study No:
NCT03277729
Phase:
Phase I/II
Press and news
SCCA providers are often asked to give their medical advice for press and news publications. Read articles by or about this SCCA provider.
Expert Sheds Light on Future of Treatment in CLL
By Targeted Oncology -
Published October 9, 2018
Study Finds Possible Link Between Allergies and Increased Risk of Hematologic Cancers in Women
By The ASCO Post -
Published November 22, 2013